Tumor Site Articles & Analysis
21 news found
Thus, host responses to cellular stress can influence various stages of cancer development and progression. Tumor cell-derived vascular endothelial growth factors (VEGFs) act on endothelial cells to promote angiogenesis and tumor growth, invasion, and metastasis. At tumor sites, monocytes differentiate into ...
“Objective responses showcased rigosertib’s KRAS mutation-agnostic mechanism of action, as each responding patient had a tumor with a different underlying variant. This differentiates rigosertib from agents targeting a single KRAS mutation variant, and positions it to potentially address the unmet needs of a much broader patient population. ...
The paper also found that inhibition of this function of PAD4 reduces primary tumor growth and metastasis and enhances checkpoint inhibitor treatments. ...
Importantly, despite high proportions of differentiated cells, only very low levels of IFNα were detected in plasma or in cerebrospinal fluid, consistent with the Company's expectation that IFNα expression remains tightly regulated outside the tumor sites. Temferon treatment continues to demonstrate a good safety profile, with manageable serious ...
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces that preliminary findings from its Phase 1/2a of Temferon™ in the treatment of patients with glioblastoma multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM) provide initial evidence of ...
CT Abstract Summary: Interleukin 12 (IL12) is an attractive cancer immunotherapeutic known to be extremely potent against solid tumors preclinically. However, the clinical utility of IL12 has been limited by toxicities stemming from systemic cytokine exposure. ...
The current standard of care for patients with operable malignant glioma tumors is surgical removal of the tumor followed by radiation and chemotherapy. ...
Only 20%-30% of patients with liver tumors are eligible for surgical resection due to the presence of multiple tumors, underlying poor liver function, or general health issues limiting the success of surgery. Primary liver tumors were the third leading cause of tumor related death worldwide in 2020, with approximately 906,000 ...
Maciej Pech, Interventional Radiologist, Director of University Clinic for Radiology and Nuclear Medicine and Principal Investigator of the #HOPE4LIVER site in Magdeburg, Germany. Professor Pech commented, “The first treatment in the #HOPE4LIVER was successful in destroying the targeted tumor and the patient performed well both during and after the ...
The Jerome Canady Research Institute for Advanced Biological and Technological Sciences, LLC (JCRI-ABTS) and US Medical Innovations, LLC (USMI) announced today that they have successfully completed Phase 1 in their Clinical Trial using Canady Helios™ Cold Plasma (CHCP) for the treatment of recurrent and stage 4 solid tumors (IDE #G190195). The medical centers involved in ...
” Only 20%-30% of patients with liver tumors are eligible for surgical resection due to the presence of multiple tumors, underlying poor liver function, or general health issues limiting the success of surgery. ...
Great care with an emphasis on precision must be taken to ensure that critical structures and tissues avoid collateral damage when possible. However, given the surgical site often lies in soft tissue, exact identification of the native tumor bed can present some difficulty for radiation planning. ...
The number of patients in the US who have primary liver tumors has increased 43% in the past 16 years and is expected to grow another 40% by 2030. The liver is second only to lymph nodes as the most common site of metastatic tumors, those that spread from other organs, and estimated to be present in up-to 70% of patients with advanced disease ...
Two features make CTT1403 unlike other PSMA-targeted drugs currently in development: 1) Due to a unique core scaffold, CTT’s molecules bind irreversibly to PSMA and this distinctive mode of binding enables rapid uptake of the drug within the tumor; and 2) CTT1403 is engineered to increase the circulation time of the drug in the body which further substantially increases the ...
With oncoplastic surgery, the lumpectomy site rarely correlates with the incisional scar and presence or absence of a seroma can no longer be counted on to correlate with the lumpectomy bed. ...
BetaGlue’s radioactive matrix and proprietary catheter can deliver radiation therapy very precisely to the tumour site and has demonstrated its efficacy preclinically. It is now an exciting time for the company as it is entering into clinical testing for difficult to treat tumors” said Geoffroy De Ribains. ...
Accurately is the operative word, yet study after study evaluating clips as markers concludes they are inaccurate in depicting the precise location of the tumor site. It bears mentioning that clips improve only consistency among observers in drawing a boost target, but clip-based targeting is known to be inaccurate. ...
Researchers from Boston Children’s Hospital and MIT took mini-antibodies from alpacas Bryson and Sanchez. Then they shrunk the mini-antibodies into even smaller nanobodies and engineered these nanobodies onto CAR-T cells. During this process, they discovered a new form of cell therapy. The goal is to enhance CAR-T cells’ targeting abilities by targeting immunosuppressive proteins in ...
ByIMAPAC
This distinctive mode of binding enhances uptake and results in rapid and extensive internalization of these drugs by tumor cells, leading to increased uptake within the tumor. CTT1403 is labeled with the radionuclide 177-Lutetium and, unlike other PSMA-targeted drugs in clinical development, contains a unique albumin binding component. The albumin binding moiety ...
Using the superior imaging properties of MRI, the applicators can be positioned more precisely allowing for more accurate delivery of radiation to the tumor site while avoiding healthy surrounding organs and tissue. C4 Imaging recently received FDA 510(k) clearance for Orion. ...